HeyJaredBeta Finch - Pharma & Biotech - EN
Leading pharmaceutical and biotechnology companies. AI-powered earnings call analysis for Pharma & Biotech (PHARMA). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.
- Indexed episodes, last 90 days
- 10
- Latest publication
- Aug 29, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 15, 2026
Latest episodes
Zoetis Q2 2026 Earnings Analysis (opens the original)
Read excerpt
More earnings analysis: https://betafinch.com Groups: PHARMA ( https://betafinch.com/groups/PHARMA) ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, where we take the numbers and the noise from corporate earnings calls and turn them into something you can actually digest. I'm Alex. JORDAN: And I'm Jordan. Today we're diving into Zoetis, ticker ZTS, the animal health giant. Q2 2026 results, and Alex, this one's a bit of a bumpy ride. ALEX: It really is. But before we ge
Vertex Pharmaceuticals Q2 2026 Earnings Analysis (opens the original)
Read excerpt
More earnings analysis: https://betafinch.com Groups: PHARMA ( https://betafinch.com/groups/PHARMA) ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Vertex Pharmaceuticals' second quarter 2026 results — and there's a lot going on: strong numbers, a major acquisition, and pipeline news across four disease areas. Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing w
Pfizer Q2 2026 Earnings Analysis (opens the original)
Read excerpt
More earnings analysis: https://betafinch.com Groups: PHARMA ( https://betafinch.com/groups/PHARMA) ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Pfizer's second quarter 2026 results, and there's a lot to unpack — from a CFO transition to some really important pipeline news. Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered inv
Merck Q2 2026 Earnings Analysis (opens the original)
Read excerpt
More earnings analysis: https://betafinch.com Groups: PHARMA ( https://betafinch.com/groups/PHARMA) ────────── Welcome to Beta Finch, your AI-powered earnings breakdown for the news that's moving your portfolio. ALEX: Hey everyone, welcome back to Beta Finch! I'm Alex, here with Jordan as always, and today we're digging into Merck's second quarter 2026 numbers. Before we get into it — quick disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing
Eli Lilly Q2 2026 Earnings Analysis (opens the original)
Read excerpt
More earnings analysis: https://betafinch.com Groups: PHARMA ( https://betafinch.com/groups/PHARMA) ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into Eli Lilly's Q2 2026 results, and Jordan, I'll just say it up front — this was a big one. JORDAN: Big is an understatement. But before we get into the numbers, our standard reminder: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be co
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.